HC Wainwright Reiterates Buy Rating for enGene Therapeutics

HC Wainwright has reiterated its buy rating for enGene Therapeutics Inc. (NasdaqCM:ENGN) as of June 16, 2026. Analyst Andres Y. Maldonado set a price target of $4, while shares of the biotechnology company are currently trading at about $1.77.

enGene Therapeutics Stock Snapshot

Shares of enGene Therapeutics, trading under the ticker ENGN on the Nasdaq Capital Market, are priced around $1.77. The company, which operates in the biotechnology sector, has a market capitalization of $117.2 million. Despite having no meaningful P/E ratio due to lack of profitability, enGene's stock has a 52-week low of $1.40 and a high of $12.25. The 50-day moving average is $4.33, while the 200-day moving average is $7.13. The company maintains a strong current ratio of 12.57 and a quick ratio of 12.07, with a debt-to-equity ratio of 13.07.

Other Institutional Activity in enGene Therapeutics

Several institutional investors have been active in enGene Therapeutics. FCPM III Services B.V. holds 9,632,561 shares valued at approximately $65.6 million, with no change in its position. Perceptive Advisors LLC slightly reduced its stake by 41,570 shares, now holding 5,827,506 shares worth about $39.7 million. Meanwhile, Siren, L.L.C. increased its holdings significantly by 1,916,895 shares, bringing its total to 5,253,159 shares valued at $35.8 million. Blue Owl Capital Holdings LP also expanded its position by 1,055,416 shares, ending with 4,416,353 shares valued at $30.1 million.

Insider Buying and Selling at enGene Therapeutics Inc.

In January 2026, several insiders at enGene Therapeutics made notable purchases. CEO Ronald H. W. Cooper acquired 801,000 shares, while other executives, including Chief Technology Officer Joan Connolly and Chief Development Officer Jill Buck, each purchased 195,000 shares. These transactions were not made under any pre-planned trading program.

Analysts Set New Price Targets

On June 16, 2026, HC Wainwright & Co. maintained its buy rating for enGene Therapeutics with a $4 price target. Earlier, UBS and Wells Fargo both set a hold rating with a $2 target, while Piper Sandler downgraded the stock to hold with a $4 target. The consensus among analysts is a buy rating, with a mean price target of $3.57 based on seven opinions.

About enGene Therapeutics

enGene Therapeutics Inc. is a clinical-stage biotechnology company based in Montreal, Canada. The company focuses on developing genetic medicines, particularly for bladder cancer patients. Its lead product is detalimogene voraplasmid, a monotherapy for non-muscle invasive bladder cancer. enGene is also advancing its LEGEND pipeline, currently in Phase 2 trials. The company was previously known as enGene Holdings Inc. before rebranding in April 2026. Ronald H. W. Cooper serves as the CEO, and the company employs 81 people.

Bottom Line

HC Wainwright's reiterated buy rating for enGene Therapeutics highlights ongoing interest despite the stock's current trading price. Investors track such ratings to gauge potential growth, though it's worth noting that these are backward-looking assessments. The company's strategic focus on genetic medicine and insider buying activity may signal confidence in its future prospects.